AB Science announces positive top-line Phase 3 results for oral masitinib in severe asthma

    NEXT STORY
    SEngine Precision Medicine’s PARIS® Test Identifies Novel Drug Combinations for PARP Inhibitor Resistant Ovarian Cancer in Study Published in EBioMedicine
    PREV STORY
    Theranostics: Global Markets
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    United Rheumatology Names Jim Albano as Chief Operating Officer

    author_avatar
    NASDAQ Market News

    Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037

    author_avatar
    NASDAQ Market News

    Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on February 27

    SOUTH SAN FRANCISCO, Calif., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. ...

    author_avatar
    NASDAQ Market News